STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) CEO’s family trusts sell 32,564 common shares in May 2026

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of 32,564 shares of common stock, executed on May 22, 2026 and May 26, 2026.

The sales were made by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, where Coloma and his spouse serve as co-trustees. Reported prices were weighted averages around $26.00 per share, across multiple trades within narrow price ranges.

Following the latest transactions, the Coloma Family Trust held 350,987 shares and The Coloma 2021 Irrevocable Trust held 28,523 shares of Maze Therapeutics common stock. One of the transactions was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating a scheduled selling program rather than purely discretionary timing.

Positive

  • None.

Negative

  • None.

Insights

CEO-related trusts sold 32,564 Maze shares under a pre-set plan.

Maze Therapeutics’ CEO, Jason V. Coloma, reported indirect open-market sales totaling 32,564 shares of common stock across two dates in May 2026. All transactions were coded as open-market sales of non-derivative common stock.

The shares are held in the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, where Coloma and his spouse act as co-trustees, so the activity reflects trust portfolio decisions rather than direct personal holdings. After these sales, the Family Trust held 350,987 shares and the Irrevocable Trust held 28,523 shares.

A key detail is that at least one sale was executed under a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans pre-schedule trades, so the timing signal is weaker than a fully discretionary sale. With no derivative positions reported, this looks like routine equity sales from existing indirect holdings.

Insider Coloma Jason V
Role Chief Executive Officer
Sold 32,564 shs ($847K)
Type Security Shares Price Value
Sale Common Stock 25,582 $26.015 $666K
Sale Common Stock 4,504 $26.0001 $117K
Sale Common Stock 2,478 $26.00 $64K
Holdings After Transaction: Common Stock — 350,987 shares (Indirect, Coloma Family Trust)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.105 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.09 per share, inclusive.
Total shares sold 32,564 shares Net open-market sales by CEO-related trusts in May 2026
Sale price (weighted average, 2026-05-26) $26.015 per share Common stock sold by Coloma Family Trust
Sale price (weighted average, 2026-05-22, Trust) $26.000 per share Common stock sold by The Coloma 2021 Irrevocable Trust
Sale price (weighted average, 2026-05-22, Family Trust) $26.0001 per share Common stock sold by Coloma Family Trust
Family Trust holdings after sales 350,987 shares Coloma Family Trust Maze common stock after May 26, 2026 sale
Irrevocable Trust holdings after sales 28,523 shares The Coloma 2021 Irrevocable Trust Maze common stock after May 22, 2026 sale
10b5-1 plan adoption date February 6, 2026 Date CEO adopted Rule 10b5-1 trading plan
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Irrevocable Trust financial
"These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust")."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
non-derivative financial
"transaction_type: "non-derivative""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coloma Jason V
(Last)(First)(Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026S(1)4,504D$26.0001(2)376,569IColoma Family Trust(3)
Common Stock05/22/2026S(1)2,478D$2628,523IThe Coloma 2021 Irrevocable Trust(4)
Common Stock05/26/2026S(1)25,582D$26.015(5)350,987IColoma Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.105 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.
3. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
4. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.09 per share, inclusive.
/s/ Courtney Phillips, as attorney-in-fact05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Maze Therapeutics (MAZE) disclose in this Form 4?

Maze Therapeutics disclosed that trusts associated with CEO Jason V. Coloma sold 32,564 shares of common stock in open-market transactions in May 2026, at weighted average prices around $26 per share, while retaining substantial remaining indirect holdings.

How many Maze Therapeutics (MAZE) shares were sold and at what prices?

Trusts linked to the Maze Therapeutics CEO sold a total of 32,564 common shares. Reported weighted average prices were approximately $26.015, $26.000, and $26.0001 per share, with individual trades occurring in narrow ranges between $26.00 and about $26.105 per share.

Were the Maze Therapeutics (MAZE) insider sales made under a Rule 10b5-1 plan?

Yes. One of the reported Maze Therapeutics insider sales was executed under a Rule 10b5-1 trading plan adopted on February 6, 2026, indicating the transaction followed a pre-arranged schedule rather than being timed solely at the insider’s discretion.

Who actually holds the Maze Therapeutics (MAZE) shares involved in these insider sales?

The shares are held indirectly by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust. Jason V. Coloma, Maze Therapeutics’ CEO, and his spouse serve as co-trustees of these trusts, which directly own the reported Maze common stock positions.

Do these Maze Therapeutics (MAZE) insider sales involve stock options or derivatives?

No. All reported transactions involve non-derivative Maze Therapeutics common stock. The derivative position summary in the filing is empty, indicating no option exercises, conversions, or other derivative transactions were reported alongside these trust share sales.